US OptionsDetailed Quotes
RXST250117P37500
- 4.63
- 0.000.00%
15min DelayClose Jan 17 16:00 ET
0.00High0.00Low
4.63Open4.63Pre Close0 Volume3 Open Interest37.50Strike Price0.00Turnover0.00%IV-8.16%PremiumJan 17, 2025Expiry Date7.11Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma4.44Leverage Ratio--Theta--Rho--Eff Leverage--Vega
RxSight Stock Discussion
Sign in to post a comment
» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...
9
3
The recent insider sale of RxSight shares and the absence of insider purchases over the last year raise concerns about the company's outlook. Despite significant insider ownership, the lack of insider buying does not inspire confidence in the company's prospects.
2
Investor confidence in RxSight appears bolstered by its high future revenue growth expectations and strong performance, resulting in a high P/S ratio. Investors seem willing to pay more for anticipated growth.
The company seems well equipped to manage its cash burn, potentially securing more funds for its expansion with minimal dilution or borrowing. Revenue growth paints a bright future for the firm, while the slight reduction in cash burn isn't concerning, given its mid-term expenditure needs.
Despite recent insider selling, the insiders still own shares worth about US$105m, or 11% of the company. However, the absence of insider buying raises cautiousness about the stock's outlook.
Gainers:
In reaction to earnings/guidance:
• $GoodRx (GDRX.US)$ +38.5%, $EDGIO (EGIO.US)$ +13.5%, $Lemonade (LMND.US)$ +10.7%, $Desktop Metal (DM.US)$ +8.5%, $ShockWave Medical (SWAV.US)$ +8.2%, $Pubmatic (PUBM.US)$ +8.1%, $Olaplex (OLPX.US)$ +7%, $Vivid Seats (SEAT.US)$ +6.4%, $Noble (NE.US)$ +6.3%, $Aspen Technology (AZPN.US)$ +5.4%, $AAON Inc (AAON.US)$ +5%, $Hudbay Minerals (HBM.US)$ +5%, $Vivint Smart Home (VVNT.US)$ +4.9%, $Vivint Smart Home (VVNT.US)$ +4...
In reaction to earnings/guidance:
• $GoodRx (GDRX.US)$ +38.5%, $EDGIO (EGIO.US)$ +13.5%, $Lemonade (LMND.US)$ +10.7%, $Desktop Metal (DM.US)$ +8.5%, $ShockWave Medical (SWAV.US)$ +8.2%, $Pubmatic (PUBM.US)$ +8.1%, $Olaplex (OLPX.US)$ +7%, $Vivid Seats (SEAT.US)$ +6.4%, $Noble (NE.US)$ +6.3%, $Aspen Technology (AZPN.US)$ +5.4%, $AAON Inc (AAON.US)$ +5%, $Hudbay Minerals (HBM.US)$ +5%, $Vivint Smart Home (VVNT.US)$ +4.9%, $Vivint Smart Home (VVNT.US)$ +4...
24
11
Gainers:
• $Canoo (GOEV.US)$ +71.3% (receives purchase order of 4500 Canoo Electric Delivery Vehicles from Walmart)
• $Aldeyra Therapeutics (ALDX.US)$ +14.1% (achieved primary endpoints in dry eye disease chamber crossover clinical trial)
• $Westport Fuel (WPRT.US)$ +10.9% (awarded 38 mln program)
• $Greenwich LifeSciences (GLSI.US)$ +5.9% (FDA has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed...
• $Canoo (GOEV.US)$ +71.3% (receives purchase order of 4500 Canoo Electric Delivery Vehicles from Walmart)
• $Aldeyra Therapeutics (ALDX.US)$ +14.1% (achieved primary endpoints in dry eye disease chamber crossover clinical trial)
• $Westport Fuel (WPRT.US)$ +10.9% (awarded 38 mln program)
• $Greenwich LifeSciences (GLSI.US)$ +5.9% (FDA has removed the clinical hold permitting the Flamingo-01 Phase III clinical trial to proceed...
14
3
Upgrades
• $Afya Ltd (AFYA.US)$: Credit Suisse Upgrades to Outperform from Neutral - PT $19 (from $18)
• $Appfolio (APPF.US)$: KeyBanc Upgrades to Overweight from Sector Weight - PT $143
• $C.H. Robinson Worldwide (CHRW.US)$: JPMorgan Upgrades to Overweight from Neutral - PT $117 (from $91)
• $Coupang (CPNG.US)$: Goldman Sachs Upgrades to Conviction Buy from Buy - PT $37
• $Gatos Silver(Delisted) (GATO.US)$: RBC Capital Upgrades to Sector Perform from Underperform - PT $4
• $ITT Inc (ITT.US)$: UBS Upgr...
• $Afya Ltd (AFYA.US)$: Credit Suisse Upgrades to Outperform from Neutral - PT $19 (from $18)
• $Appfolio (APPF.US)$: KeyBanc Upgrades to Overweight from Sector Weight - PT $143
• $C.H. Robinson Worldwide (CHRW.US)$: JPMorgan Upgrades to Overweight from Neutral - PT $117 (from $91)
• $Coupang (CPNG.US)$: Goldman Sachs Upgrades to Conviction Buy from Buy - PT $37
• $Gatos Silver(Delisted) (GATO.US)$: RBC Capital Upgrades to Sector Perform from Underperform - PT $4
• $ITT Inc (ITT.US)$: UBS Upgr...
16
1
1
No comment yet
Stock_Drift OP : $RxSight (RXST.US)$